title: Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation.
abstract: We report here a 47-year-old male with the diagnosis of high-grade B-cell lymphoma and hemophagocytosis accompanying disseminated intravascular coagulation (DIC). Lymphoma-associated hemophagocytic syndrome (LAHS) is a life-threatening disorder, and LAHS secondary to B-cell lymphoma is relatively rare compared to that secondary to T- or NK/T-cell lymphoma in Western countries. T- or NK/T-cell LAHS is sometimes combined with DIC, which makes patients' outcomes even worse, but few reports of B-cell LAHS accompanying DIC has been published so far. We successfully treated a patient with this condition with recombinant thrombomodulin (rTM), a novel agent for DIC. We believe that rTM is a therapeutic option in cases with B-cell LAHS accompanying DIC.
authors.affiliation: Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Uni
authors.forename: Akihide
authors.initials: A
authors.lastname: Yoshimi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Maki
authors.forename: Daichi
authors.initials: D
authors.lastname: Maeda
authors.forename: Kumi
authors.initials: K
authors.lastname: Nakazaki
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Nakamura
authors.forename: Masashi
authors.initials: M
authors.lastname: Fukayama
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001856:Bone Marrow Examination; D003520:Cyclophosphamide / Q000008:administration & dosage; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D010257:Paraneoplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D000069283:Rituximab; D018180:Thrombomodulin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D011994:Recombinant Proteins; D018180:Thrombomodulin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: B-cell lymphoma; disseminated intravascular coagulation; lymphoma-associated hemophagocytic syndrome; recombinant thrombomodulin